Hims & Hers Stock (HIMS) Plunges Despite Launch of Affordable Healthcare Platform
Hims & Hers Health shares continued their downward trajectory on Thursday, unaffected by the rollout of its new 'affordable' healthcare platform, Labs. The California-based telehealth company aims to democratize access to laboratory test results and personalized health insights—previously a luxury for the wealthy—through subscription-based plans.
Market skepticism persists despite the platform's promise of actionable health metrics, including heart health and hormone levels, paired with physician-developed treatment plans. The launch coincides with a 21% annual decline in app downloads and a 14% drop in web traffic, signaling broader challenges in user engagement.